Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

Hidalgo-Vega, Álvaro; Villoro, Renata; Blasco, Juan Antonio; Talavera, Pablo; Ferro, Belén; Purcaru, Oana

doi:10.1186/s12962-015-0037-9

Cost Effectiveness and Resource Allocation

Table 6 One way sensitivity analysis for the ICER of certolizumab pegol vs. monotherapies

From: Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

Parameter	Base case estimate	Sensitivity estimate	Comparator to certolizumab pegol (incremental cost per QALY gained)
Parameter	Base case estimate	Sensitivity estimate	Adalimumab (every 2 weeks)	Adalimumab (weekly)	Etanercept
Base case results			CZP dominates	CZP dominates	8,778^a
Time horizon	Lifetime	5 years	29,944	CZP dominates	5,537^a
Time horizon	Lifetime	10 years	11,327	CZP dominates	8,033^a
Discount rate	Costs and QALYs 3.5 %	Costs 1.5 % and QALYs 1.5 %	CZP dominates	CZP dominates	11,131^a
		Costs 1.5 % and QALYs 6 %	CZP dominates	CZP dominates	13,572^a
		Costs 6 % and QALYs 1.5 %	CZP dominates	CZP dominates	5,481^a
		Costs 6 % and QALYs 6 %	CZP dominates	CZP dominates	6,683^a
Inflation	3.0 %	0 %	CZP dominates	CZP dominates	11,017^a
ACR response	6 months	3 months	17,919^a	593.646^a	ETA dominates
Baseline HAQ score	1.6	1	206,601^a	1.735.397^a	88,132
Baseline HAQ score	1.6	2.5	16,918	CZP dominates	11,394^a
Rebound assumption, back to baseline	100 %	50 %	21,616	CZP dominates	61,234^a
Perspective	SNS	Societal	CZP dominates	CZP dominates	ETA dominates
Drug costing	Per mg	Per unit	CZP dominates	CZP dominates	7,928^a
Principle QoL instrument	EQ-5D	HAQ DI	2457	CZP domina	380^a
Association between HAQ DI and mortality	RR of 1.33 per HAQ DI increment	No association (RR of 1)	CZP domina	CZP domina	11,418^a
Administration Cost of IV medication in day hospital	214,54 €	+20 % (257,44 €)	subcutaneous injections	subcutaneous injections	subcutaneous injections
Administration Cost of IV medication in day hospital	214,54 €	−20 % (171,63 €)	subcutaneous injections	subcutaneous injections	subcutaneous injections

^aICER is of adalimumab or etanercept against CZP, rather than vice versa, as elsewhere

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com